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Megalizzi et al.’s data showing reduction of glioblastoma
cells’ motility by the experimental sigma-1 agonist 4-IBP [1]
is delightful news. Since we already have several approved
and marketed drugs with potent sigma-1 agonist activity
we can start looking at treatment consequences of their
data now.
The antidepressant drug fluvoxamine is an old, generic,
selective serotonin reuptake inhibitor with quite potent
sigma-1 agonist activity [2,3]. Donepizil is a cholinester-
ase inhibitor used for over a decade in the treatment of
Alzheimer’s disease that has coincidentally high affinity
and agonist activity at the sigma-1 receptor [4]. Dextro-
methorphan is an old anti-tussive that although weak in that
role, does have sigma-1 agonist activity [5,6]. Memantine,
FDA approved for treatment of Alzheimer’s dementia, also
has some agonist activity at sigma-1 [7].
Caution is warranted though because sigma-1 antago-
nists have shown pro-apoptosis effects in breast cancer and
other cancer models [for example ref. 8].
Haloperidol, one of the oldest drugs still in wide use as an
anti-psychotic medicine, is also used commonly to treat
delirium, including post-operative delirium. This would per-
haps be ill-advised after glioblastoma surgery if the data of
Megalizzi et al. [1] mean that sigma-1 agonism can restrict
this cancer’s extreme motility. Haloperidol in low and com-
monly used doses, shows high affinity antagonism of the
sigma-1 receptor [9,10].
So we have available drugs to inhibit or stimulate the
sigma-1 receptor as the clinical situation requires. Given
the easy tolerability of the above sigma-1 agonists, careful
follow-up studies should be done to explore the conclusions
of Megalizzi’s work.
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